Register for our free email digests:
Latest From Hyperion Therapeutics Inc.
Horizon's deal to buy River Vision to bolster its orphan product pipeline is cast into the shade by a disappointing first quarter performance for its primary care business.
Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.
Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.
Japanese firm Santen Pharmaceutical is reorganizing its business to have a sole focus on ophthalmology.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- ImmuNext Inc.
- Senior Management
David DeLucia, CEO
Randolph Noelle, PhD, CSO
- Contact Info
1 Medical Ctr. Dr.
Lebanon, NH 03756
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.